Infectious Complications in Biologic and Targeted Therapies
Overview on the risk of infection associated with biologic and targeted therapies.- Timeline of infections associated with biologic and targeted therapies.- Infectious disease evaluation of candidates to new therapies.- Vaccines and biologic and targeted therapies.- Travel and risk of infections.- Anti-necrosis tumoral factor-alpha agents.- CD19-targeted agents.- CD20-targeted agents.- CD22-targeted agents.- CD30-targeted agents.- CD33 and CD38-targeted agents.- CD40 and CD319-targeted agents.- CD52-targeted agents.- CCR4-targeted agents.- Cell-surface receptors I: VEFG targeted agents.- Cell-surface receptors II: Epidermal growth factor receptor-targeted agents.- Interleukin-1 targeted agents.- Interleukin-5 and interleukin-6 targeted agents.- Interleukin-12/23 p40 targeted agents.- Sphingosine-1 phosphate receptor modulators.- Immune checkpoint inhibitors.- ¿4-integrin-targeted agents.- Tyrosin-kinase inhibitors.- Bcl-2, JAK and mTOR inhibitors.- Infections associated with the use ofCarT cells.- Pulmonary infiltrates.- Tuberculosis.- Cytomegalovirus and other herpesviruses.- Invasive fungal infections.- Progressive multifocal leukoencephalopathy.- Hepatitis virus.
Mehr anzeigenSofort verfügbar, Lieferzeit: 1-3 Tage
Nur noch 1 Artikel verfügbar!
Weitere Infos zum Zustand
29,90 €
Preise inkl. MwSt. zzgl. Versandkosten
14 Tage Zufriedenheitsgarantie
Risikofrei bestellen
Geprüfte Gebrauchtware
Einzeln geprüft
Produktinformationen "Infectious Complications in Biologic and Targeted Therapies"
Anmelden
Versandkostenfrei ab 29 €
14 Tage Rückgaberecht - Kein Risiko
Geprüfte Gebrauchtware